Targeting Aurora kinases in ovarian cancer

Siqing Fu, Wei Hu, John J. Kavanagh, Robert C Bast Jr

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Although recurrent epithelial ovarian cancer initially responds well to current first-line adjuvant therapy, eventually the disease becomes resistant to chemotherapy. Novel strategies are needed to reverse chemoresistance in order to treat relapsed ovarian cancer effectively. One strategy is to target aberrant expression activation of Aurora kinases that are essential for the regulation of chromosome segregation and cytokinesis during mitosis and which play a role in tumourigenesis and progression in a wide range of human tumours, including ovarian cancer. The purpose of this article is to review Aurora kinases and their inhibitors in human epithelial ovarian cancer as an impetus to the development of effective and less toxic regimens for ovarian cancer. In addition, this review tries to define the differences between cytotoxic chemotherapeutic agents and molecular therapeutic agents: both groups of agents have either a single specific target or multiple specific targets, while their differences lie in their toxicity profiles and the way to determine their dosages for further studies. The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment.

Original languageEnglish (US)
Pages (from-to)77-85
Number of pages9
JournalExpert Opinion on Therapeutic Targets
Volume10
Issue number1
DOIs
StatePublished - Feb 1 2006

Fingerprint

Aurora Kinases
Ovarian Neoplasms
Toxicity
Chromosome Segregation
Oncology
Chemotherapy
Cytokinesis
Poisons
Cytotoxins
Therapeutics
Chromosomes
Mitosis
Tumors
Chemical activation
Drug Therapy
Neoplasms

Keywords

  • Aurora kinase inhibitor
  • Aurora kinases
  • Cell cycle
  • Chemosensitisation
  • Mitosis
  • Molecular therapeutic agent
  • Ovarian cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Targeting Aurora kinases in ovarian cancer. / Fu, Siqing; Hu, Wei; Kavanagh, John J.; Bast Jr, Robert C.

In: Expert Opinion on Therapeutic Targets, Vol. 10, No. 1, 01.02.2006, p. 77-85.

Research output: Contribution to journalReview article

@article{a238b8f5516643c8aff5042e50fa9cee,
title = "Targeting Aurora kinases in ovarian cancer",
abstract = "Although recurrent epithelial ovarian cancer initially responds well to current first-line adjuvant therapy, eventually the disease becomes resistant to chemotherapy. Novel strategies are needed to reverse chemoresistance in order to treat relapsed ovarian cancer effectively. One strategy is to target aberrant expression activation of Aurora kinases that are essential for the regulation of chromosome segregation and cytokinesis during mitosis and which play a role in tumourigenesis and progression in a wide range of human tumours, including ovarian cancer. The purpose of this article is to review Aurora kinases and their inhibitors in human epithelial ovarian cancer as an impetus to the development of effective and less toxic regimens for ovarian cancer. In addition, this review tries to define the differences between cytotoxic chemotherapeutic agents and molecular therapeutic agents: both groups of agents have either a single specific target or multiple specific targets, while their differences lie in their toxicity profiles and the way to determine their dosages for further studies. The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment.",
keywords = "Aurora kinase inhibitor, Aurora kinases, Cell cycle, Chemosensitisation, Mitosis, Molecular therapeutic agent, Ovarian cancer",
author = "Siqing Fu and Wei Hu and Kavanagh, {John J.} and {Bast Jr}, {Robert C}",
year = "2006",
month = "2",
day = "1",
doi = "10.1517/14728222.10.1.77",
language = "English (US)",
volume = "10",
pages = "77--85",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Targeting Aurora kinases in ovarian cancer

AU - Fu, Siqing

AU - Hu, Wei

AU - Kavanagh, John J.

AU - Bast Jr, Robert C

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Although recurrent epithelial ovarian cancer initially responds well to current first-line adjuvant therapy, eventually the disease becomes resistant to chemotherapy. Novel strategies are needed to reverse chemoresistance in order to treat relapsed ovarian cancer effectively. One strategy is to target aberrant expression activation of Aurora kinases that are essential for the regulation of chromosome segregation and cytokinesis during mitosis and which play a role in tumourigenesis and progression in a wide range of human tumours, including ovarian cancer. The purpose of this article is to review Aurora kinases and their inhibitors in human epithelial ovarian cancer as an impetus to the development of effective and less toxic regimens for ovarian cancer. In addition, this review tries to define the differences between cytotoxic chemotherapeutic agents and molecular therapeutic agents: both groups of agents have either a single specific target or multiple specific targets, while their differences lie in their toxicity profiles and the way to determine their dosages for further studies. The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment.

AB - Although recurrent epithelial ovarian cancer initially responds well to current first-line adjuvant therapy, eventually the disease becomes resistant to chemotherapy. Novel strategies are needed to reverse chemoresistance in order to treat relapsed ovarian cancer effectively. One strategy is to target aberrant expression activation of Aurora kinases that are essential for the regulation of chromosome segregation and cytokinesis during mitosis and which play a role in tumourigenesis and progression in a wide range of human tumours, including ovarian cancer. The purpose of this article is to review Aurora kinases and their inhibitors in human epithelial ovarian cancer as an impetus to the development of effective and less toxic regimens for ovarian cancer. In addition, this review tries to define the differences between cytotoxic chemotherapeutic agents and molecular therapeutic agents: both groups of agents have either a single specific target or multiple specific targets, while their differences lie in their toxicity profiles and the way to determine their dosages for further studies. The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment.

KW - Aurora kinase inhibitor

KW - Aurora kinases

KW - Cell cycle

KW - Chemosensitisation

KW - Mitosis

KW - Molecular therapeutic agent

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=33144484510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144484510&partnerID=8YFLogxK

U2 - 10.1517/14728222.10.1.77

DO - 10.1517/14728222.10.1.77

M3 - Review article

C2 - 16441230

AN - SCOPUS:33144484510

VL - 10

SP - 77

EP - 85

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -